key: cord-1038490-d6by9p41 authors: Khan, Suliman; Siddique, Rabeea; Shereen, Muhammad Adnan; Ali, Ashaq; Liu, Jianbo; Bai, Qian; Bashir, Nadia; Xue, Mengzhou title: Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options date: 2020-04-23 journal: J Clin Microbiol DOI: 10.1128/jcm.00187-20 sha: b40db19fae95ded4cc57d3eb19e0e54b807f13c5 doc_id: 1038490 cord_uid: d6by9p41 The new decade of the 21(st) century (2020) started with the emergence of a novel coronavirus known as SARS-CoV-2 that caused an epidemic of coronavirus disease (COVID-19) in Wuhan, China. It is the third highly pathogenic and transmissible coronavirus after severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in humans. The source of origin, transmission to humans, and mechanisms associated with the pathogenicity of SARS-CoV-2 are not yet clear, however, its resemblance to SARS-CoV and several other bat coronaviruses was recently confirmed through genome sequencing-related studies. The development of therapeutic strategies is necessary in order to prevent further epidemics and cure infections. In this review, we summarize current information about the emergence, origin, diversity, and epidemiology of three pathogenic coronaviruses with a specific focus on the current outbreak in Wuhan, China. Furthermore, we discuss the clinical features and potential therapeutic options that may be effective against SARS-CoV-2. the onset of fever and respiratory symptoms occurred approximately 3 to 6 days after presumptive exposure (41) . Diagnostic testing for the SARS-CoV-2 is primarily done in public health laboratories. Delays in testing result from the need for administrative oversight of testing at the national or regional level, as well as the time needed to transport specimens and the high volume of testing needed in some regions. More rapid testing should be widely available in the event of epidemics. High-level testing facilities at regional hospitals and commercial laboratories are needed, in addition to the commercially available tests that have undergone regulatory approval. Several tests have been validated by public health authorities, including those in China, Germany, Thailand, Japan, and the United States (WHO, COVID-19, technical guidance, Feb 12, 2020) . These tests are reverse transcriptase PCR (RT-PCR) tests that use primers and probes designed to detect a variety of targets in the SARS-CoV-2 genome. Although these have been designed and validated, there is currently very limited information available related to the performance of these tests. The sensitivity and specificity of the tests are not widely known, and some of them might detect other related coronaviruses, such as SARS-CoV. In addition, the utility of different specimen types for detection of the viruses is not known. As a result, testing of multiple specimen types is recommended by some agencies, including the CDC (42) . The availability of serological tests is unclear and, presumably, such tests are in development. Moreover, the collection and submission of sera from potentially infected patients is recommended by some public health laboratories. The CDC and WHO have both issued recommendations for laboratory safety when testing specimens from patients suspected of being infected with SARS-CoV-2 (42, 43) . Both guidelines recommend that manipulation of potentially infectious specimens should be done in a biosafety cabinet if there is potential for splashes or generation of droplets or aerosols. Viral isolation (culture) should be done only in BL-3 laboratories. Testing in chemistry and hematology laboratories can be done following routine laboratory precautions recommended for such work. Currently there are no promising antiviral treatments available, however, numerous compounds have been proven effective against SARS-CoV and MERS-CoV but have not been tested widely for the newly emerged SARS-CoV-2. Remdesivir and chloroquine were found highly effective in vitro for the control of 2019-nCoV infection (44) . Treatment with remdesivir alone or in combination with chloroquine or interferon beta was found effective against COVID-19 infection. This strategy has not caused any obvious side effects yet (35, 44, 45) . However, more investigations are necessary to confirm the impacts of remdesivir. As coronaviruses share key genomic elements, common therapeutic targets are likely to be of greater importance. Therapeutic agents targeting nucleosides, nucleotides, viral nucleic acids, and enzymes/proteins involved in the replication and transcription of coronaviruses can be promising strategies to treat coronavirus diseases (Table 1 ) (1). The surface spike glycoprotein (S) is an important potential target for antiviral agents, due to its vital role in the interaction between the virus and the cell receptor. S consists of two subunits: S1, the amino-terminal receptor binding subunit, and S2, the carboxy-terminal membrane fusion subunit (46) . In addition, activation of membrane fusion and virus entry requires the cleavage at the junction of S1-S2 (46) . Hence, S1 subunit-targeting monoclonal antibodies and S2 subunit-targeting fusion inhibitors may be effective therapeutic agents for coronaviruses (1). Furin (a serine endoprotease) cleaves off S1/S2 (47) could thus be a suitable antiviral agent. Further, the helical nucleocapsid interacts with S protein, envelope proteins, and membrane proteins to form the assembled virion (1). Therefore, targeting the structural genes using small interfering RNAs could be an effective therapeutic strategy against coronaviruses (1). The host receptors are also associated with the viral Bananins Target helicase to inhibit unwinding and activity of ATPase Have effects against broad-spectrum viruses and can be evaluated for SARS-CoV-2. (1) Aryl diketoacids (Adks) Target helicase to inhibit its unwinding Effective for a broad range viruses, including SARS/MERS-CoV, and may be a suitable choice for SARS-CoV-2. (1) Targets oligosaccharides on S to block viral binding with host cell Has effects against SARS/MERS-CoV and other high pathogenic viruses, thus might be used against SARS-CoV-2. Hexamethylene amiloride Targets viral envelope to inhibit ion channel activity Has effects against different coronaviruses, thus one of the most suitable treatment options for SARS-CoV-2. Targets lipid membrane and causes modification of phospholipids Has effects against different viruses and may be promising as an anti-SARS-CoV-2 agent. (1, 60) Induce immune responses through recombinant interferons, found effective against a wide range of viruses and can be the most suitable option for SARS-CoV-2. (1, 60) Induces immune responses through recombinant interferons, has been found effective against a wide range of viruses and may be promising to use against SARS-CoV-2. Cyclosporine, alisporivir Inhibit cyclophilin to affect calcineurin-NFAT pathway Inhibit broad-spectrum viruses, specifically coronaviruses, and thus could be suitable option to treat SARS-CoV-2. (1) Inhibits kinase signaling associated pathways to block viral entry (1) entry into host cells, thus agents targeting these receptors also inhibit coronaviruses (46) . Inhibitors of endosomal cysteine protease and transmembrane protease serine 2 can partially block viral entry into the cell (48) . K22 targets membrane-bound RNA synthesis in coronaviruses and inhibits double-membrane vesicle formation (49) , and thus could be effective against SARS-CoV-2. Broad-spectrum antivirals, such as dsRNA-activated caspase oligomerizer (DRACO), which selectively induces apoptosis in virus-containing host cells, provide another class to evaluate for effectiveness against SARS-CoV-2 (50). However, this class does not provide a promising strategy alone, as they cannot block virus entry or disrupt viral nucleic acid. In contrast, thiopurine compounds, naphthalene inhibitors, protease inhibitors, zinc, and mercury conjugates target 3CLpro (3C-like protease) and PLpro (papain-like protease) enzymes in coronaviruses and have been shown to block their pathogenicity (51, 52) . Therefore, combinational therapy of these antiviral agents with DRACO may enhance the overall impact on the recovery of patients. Despite the higher rate of infectiousness, coronaviruses are thought to have the ability to suppress counteracting responses from host innate interferons. This response can be augmented by the utilization of interferon inducers or recombinant interferons (1) . Recombinant interferons such as interferon alpha and interferon beta that have been tested against SARS-CoV (1) might be utilized either alone or in combination with other potential antiviral drugs, including remdesivir. Both interferon alpha and beta inhibit viral replication (1) . The use of interferon inducers in combination with effective antiviral agents is worth evaluating for possible synergistic effects against SARS-CoV-2. In addition, calcineurin inhibitors such as cyclosporine (53) , in combination with antibiotics and traditional Chinese medicines, could also be evaluated for activity against SARS-CoV-2. Effective vaccines are important to prevent and control sporadic viral attacks and emerging virus-mediated epidemics, such as the recent outbreak caused by SARS-CoV-2. Although SARS-CoV was fully controlled during 2003, and MERS-CoV has been prevented from causing high mortality rates, the newly emerged SARS-CoV-2 is spreading efficiently with a significant increase in the number of cases and fatalities during each passing day. Vaccines are required to prevent SARS-CoV-2 from causing COVID-19. Live-attenuated vaccines, such as has been designed for SARS (1), may be evaluated for SARS-CoV-2 infected patients. In addition rhesus -defensin 1 and protein cage nanoparticles are innate immunomodulators with high anti-SARS-CoV efficiency (54, 55) . Based on the high similarity and phylogenetic relatedness between SARS-CoV and SARS-CoV-2, protein cage nanoparticles designed for SARS-CoV can be evaluated for SARS-CoV-2. Meanwhile, following similar strategies utilized for SARS-CoV, novel protein cage nanoparticles specified for novel coronavirus can be designed on an emergency basis. Given the urgency in the current scenario of COVID-19 outbreak, vaccination strategies based on viral vectors, recombinant protein, and viral-like particles, which have been developed or are being developed for SARS and/or MERS, could be modified for utilization against SARS-CoV-2 (56) . Despite the current progress, further work is needed to develop safe and effective vaccines, available for individuals at high risk of SARS-CoV-2 endemics, to control the ongoing and risk of future epidemics. Further, an interesting feature of plasma from recovered patients is the presence of active antibodies. The transfer of plasma from people who have recovered from COVID-19 into infected individuals might enhance immunity against SARS-CoV-2. Monoclonal antibodies that could inhibit virus-cell receptor binding and interrupt virus-cell fusion have been developed (1) . Combining two or more monoclonal antibodies may be suitable for the quicker recovery of patients. Lastly, antiviral peptides that target different regions of S, such as HP2P-M2 peptide (effective against viral infections) (1), should also be considered against COVID-19. Although some strategies against SARS-CoV are being developed, including receptor-binding domain (RBD)-based vaccines, they require further evaluation (2) . Given the importance of the current outbreak in Wuhan, further studies are needed to deepen understanding of replication, pathogenesis, and biological properties using reverse genetics and related molecular techniques. These investigations will help the control and prevention of SARS-CoV-2-mediated pneumonia disease and novel emerging diseases in the future. SARS-CoV and MERS-CoV were reported to originate from recombination within bat viruses before their introduction into Guangdong province through civets and the Middle East through camels, respectively. Some of the SARS-CoV strains became epidemic after several independent spillovers to humans during the outbreak of 2002 in Guangdong, China (3) . Similarly, MERS-CoV became epidemic after a series of human infections in 2012 in Middle Eastern countries (33) . Both viruses transferred to several countries beyond the countries of origin. However, unlike the continuous propagation of the MERS-CoV epidemic, the SARS-CoV outbreak was successfully controlled in 2003. Based on the origin of other coronaviruses, SARS-CoV-2 is likely to have originated in bats and have been introduced to Wuhan, China through an unknown intermediate. Until now, no effective clinical treatments or prevention strategies are available to be used against human coronaviruses. Testing drugs against coronaviruses requires suitable animal models prior to their use in humans. The currently established models are not very promising for the studies of pathogenesis and treatment of highly pathogenic coronaviruses. For instance, nonhuman primates were unable to reproduce the characteristics of the severe human disease and mortality was not observed (57) . However, some small animals have developed clinical symptoms of disease (57) , such as transgenic mice expressing human ACE2, and mouse-adapted SARS-CoV strains are one of the most suitable models (1). Additionally, transgenic mice expressing human DPP4 are a suitable small animal model for MERS (1) . Like the animal models for SARS-CoV, transgenic animal models may also be standardized for SARS-CoV-2. The development of clinical drugs for coronaviruses is challenging because of the repeated emergence of novel coronaviruses with diverse features, thus requiring specific drugs for each newly emerged virus. Moreover, only a limited number of animal models are available and most of them can only be used in highly demanding biosafety level 3 labs (1). From the perspective of the current outbreak, designing effective therapeutics for SARS-CoV-2 is yet another challenge for scientists. Although a large number of antiviral treatment options for SARS and MERS have been reported with potent in vitro activities, a very limited number of these may have potential in the clinical setting. Moving forward there are treatment options available that could be utilized clinically during the ongoing SARS-CoV-2 epidemic. Some of the broad-spectrum antiviral drugs may be effective for SARS-CoV-2, and there is opportunity to test them in the current scenario of pneumonia in Wuhan, China. Broad-range combinational therapies, including lopinavir and interferon antiviral peptides, can also be evaluated and examined, as these agents have shown significant effects against MERS in nonhuman primates (1) . The design and development of novel broad-spectrum antiviral drugs that can potentially target all coronaviruses may prove to be the best treatment option against reemerging and circulating coronaviruses. Coronavirusesdrug discovery and therapeutic options Origin and evolution of pathogenic coronaviruses Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China MERS-CoV infection: mind the public knowledge gap Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia Novel coronavirus: how the things are in Wuhan Emerging coronaviruses: genome structure, replication, and pathogenesis The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-the latest 2019 novel coronavirus outbreak in Wuhan, China Cross-species transmission of the newly identified coronavirus 2019-nCoV Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia Kava and St. John's Wort: current evidence for use in mood and anxiety disorders Close relative of human Middle East respiratory syndrome coronavirus in bat Clinical features of patients infected with 2019 novel coronavirus in Wuhan Epidemiology, genetic recombination, and pathogenesis of coronaviruses Molecular evolution of human coronavirus genomes Analysis on the risk factors of severe acute respiratory syndromes coronavirus infection in workers from animal markets Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus Bats are natural reservoirs of SARS-like coronaviruses Zoonotic origin and transmission of Middle East respiratory syndrome coronavirus in the UAE MERS coronaviruses from camels in Africa exhibit region-dependent genetic diversity Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus Receptor usage of a novel bat lineage c betacoronavirus reveals evolution of Middle East respiratory syndrome-related coronavirus spike proteins for human dipeptidyl peptidase 4 binding Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Full genome NJ tree all CoV families Maximum likelihood tree of all outbreak sequences with orf1a region 2020 -01-23 All outbreak sequences so far are very closely Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China Description and clinical treatment of an early outbreak of severe acute respiratory syndrome Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV Middle East Respiratory Syndrome coronavirus transmission for the China Novel Coronavirus Investigating and Research Team. 2020. A novel coronavirus from patients with pneumonia in China Coronavirus disease 2019 (COVID-19), situation report -35 Feng Z. 2020. Early transmission dynamics in Transmission of 2019-nCoV infection from an asymptomatic contact in Germany A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Centers for Disease Control and Prevention. 2020. Guidelines for samples for COVID-19 Laboratory biorisk management for laboratories handling human specimens suspected or confirmed to contain novel coronavirus 2012, interim recommendations Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Washington State 2019-nCoV Case Investigation Team. 2020. First case of 2019 novel coronavirus in the United States Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2 Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the Middle East respiratory syndrome virus Broad-spectrum antiviral therapeutics The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds Antiviral drugs specific for coronaviruses in preclinical development Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses Middle East respiratory syndrome coronavirus (MERS-CoV): infection, immunological response, and vaccine development Development of animal models against emerging coronaviruses: from SARS to MERS coronavirus A systematic review of therapeutic agents for the treatment of the Middle East respiratory syndrome coronavirus (MERS-CoV) MERS-CoV papain-like protease has deISGylating and deubiquitinating activities Broad-spectrum coronavirus antiviral drug discovery Nucleoside analogues for the treatment of coronavirus infections Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models Structure and inhibition of the SARS coronavirus envelope protein ion channel Update on nitazoxanide: a multifunctional chemotherapeutic agent Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication